Skye Bioscience amends arrangement agreement with Emerald Health Therapeutics, appoints new board and changes auditor

Skye Bioscience, Inc.

Filed amendment to Arrangement Agreement with Emerald Health Therapeutics waiving closing conditions and revising post-closing board.
Dismissed Mayer Hoffman and engaged Friedman LLP as independent auditor for fiscal year 2022.
Post-closing board includes Punit Dhillon, Bobby Rai, Praveen Tyle, Margaret Dalesandro, Keith Ward; management unchanged.
Amendment removes requirement for waiver of change of control payments from Emerald Health Biotechnology Espana S.L.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.